TETRAKIS(4-METHOXYBENZENE)TIN(IV) IMMOBILISED INTO MCM-41 AND SBA-15 MESOPOROUS NANOSTRUCTURES

17th International Conference on Fundamental and Applied Aspects of Physical Chemistry (Proceedings, Volume I) (2024) [H-03-O, pp. 285-288]

AUTHOR(S) / АУТОР(И): Til J. Becker , Tamara Krajnović , Vuk Gordić , Sanja Mijatović , Danijela Maksimović-Ivanić , Evamarie Hey-Hawkins and Goran N. Kaluđerović  

Download Full Pdf   

DOI: 10.46793/Phys.Chem24I.285B

ABSTRACT / САЖЕТАК:

Tetraaryltin(IV) compounds are suitable compounds to replace platinum-based chemotherapeutics since they provide promising in vitro results. To further decrease toxicity and side effects, passive drug targeting via nanostructures can be utilised, since tumour tissues provide the ability to accumulate bigger particles than healthy ones. In this study, tetrakis(4-methoxybenzene)tin(IV) (1) is immobilised in two mesoporous silica nanostructures (MCM-41|1 and SBA-15|1), which are synthesised and characterised herein. Employing MTT and CV assays, the antitumour activity of the organotin(IV) compound against human (A375) and murine (B16) melanoma cells, as well as human (HCT116) and murine (CT26) colon cancer cells is observed for its free form and when loaded into MCM-41 and SBA-15. MCM-41|1 showed even higher activity than 1 alone against all investigated tumour cells (MC50 obtained by CV, MTT: 2.0 – 4.3 µg/mL).

KEYWORDS / КЉУЧНЕ РЕЧИ:

ACKNOWLEDGEMENT / ПРОЈЕКАТ:

This work was supported by the Landesgraduiertenstipendium, German Academic Exchange Service DAAD PPP (Project number: 57704188) and Ministry of Science, Technological Development and Innovation of the Republic of Serbia (grant No 451-03-66/2024-03/20007).

REFERENCES / ЛИТЕРАТУРА:

  • F. Tixier, F. Ranchon, A. Iltis, N. Vantard, V. Schwiertz, E. Bachy, F. Bouafia-Sauvy, C. Sarkozy, J. F. Tournamille, E. Gyan, G. Salles, C. Rioufol, Hematol. Oncol. 35 (2017) 584–590.
  • N. Đ. Pantelić, B. Božić, B. B. Zmejkovski, N. R. Banjac, B. Dojčinović, L. A. Wessjohann, G. Kaluđerović, Molecules 26 (2021) 3199.
  • M. Z. Bulatović, D. Maksimović-Ivanić, C. Bensing, S. Gómez-Ruiz, D. Steinborn, H. Schmidt, Mojić, A. Korać, I. Golić, D. Pérez-Quintanilla, M. Momčilović, S. Mijatović, G. N. Kaluđerović, Angew. Chem. Int. Ed. 53 (2014) 5982–5987.
  • A. Watermann, J. Brieger, Nanomaterials 7 (2017) 189.
  • Y. Liu, C. Wang, L. Huang, D. Xue, Synlett 31 (2020) 1613–1618.
  • Z. Tao, Y. Xie, J. Goodisman, T. Asefa, Langmuir 26 (2010) 8914–8924.
  • M. Mladenović, I. Morgan, N. Ilić, M. Saoud, M. V. Pergal, G. N. Kaluđerović, N. Ž. Knežević, Pharmaceutics 13 (2021) 460.
  • I. Predarska, M. Saoud, D. Drača, I. Morgan, T. Komazec, T. Eichhorn, E. Mihajlović, D. Dunđerović, S. Mijatović, D. Maksimović-Ivanić, E. Hey-Hawkins, G. N. Kaluđerović, Nanomaterials 12 (2022) 3767.
  • M. Thommes, K. Kaneko, A. V. Neimark, J. P. Olivier, F. Rodriguez-Reinoso, J. Rouquerol, K. W. Sing, Pure Appl. Chem. 87 (2015) 1051–1069.
  • R. Schmidt, M. Stöcker, E. Hansen, D. Akporiaye, O. H. Ellestad, Microporous Mat. 3 (1995) 443–448.